New York State Common Retirement Fund Has $76.49 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

New York State Common Retirement Fund trimmed its holdings in Repligen Co. (NASDAQ:RGEN) by 4.0% during the fourth quarter, Holdings Channel reports. The firm owned 425,412 shares of the biotechnology company’s stock after selling 17,676 shares during the quarter. New York State Common Retirement Fund’s holdings in Repligen were worth $76,489,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Park Place Capital Corp increased its holdings in Repligen by 90.2% during the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 120 shares in the last quarter. Capital Advisory Group Advisory Services LLC bought a new position in shares of Repligen in the third quarter valued at approximately $216,000. Handelsbanken Fonder AB grew its holdings in shares of Repligen by 20.3% in the third quarter. Handelsbanken Fonder AB now owns 10,733 shares of the biotechnology company’s stock valued at $1,707,000 after acquiring an additional 1,810 shares in the last quarter. Slow Capital Inc. grew its holdings in shares of Repligen by 18.9% in the third quarter. Slow Capital Inc. now owns 13,992 shares of the biotechnology company’s stock valued at $2,225,000 after acquiring an additional 2,223 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund grew its holdings in shares of Repligen by 130.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 11,500 shares of the biotechnology company’s stock valued at $1,829,000 after acquiring an additional 6,500 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $171.28 on Wednesday. The stock has a fifty day simple moving average of $186.62 and a two-hundred day simple moving average of $173.56. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The firm has a market cap of $9.56 billion, a price-to-earnings ratio of 237.89, a price-to-earnings-growth ratio of 5.16 and a beta of 1.02. The company has a current ratio of 7.02, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s revenue was down 16.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.68 earnings per share. Analysts anticipate that Repligen Co. will post 1.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RGEN. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus upped their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $196.70.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the sale, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,597 shares of company stock worth $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.